An ionic liquid-based adjuvant for modulating cellular and humoral immune responses.

Autor: Goetz MJ; John A Paulson School of Engineering & Applied Sciences, Harvard University, Allston, MA 02134, USA., Park KS; John A Paulson School of Engineering & Applied Sciences, Harvard University, Allston, MA 02134, USA., Joshi M; John A Paulson School of Engineering & Applied Sciences, Harvard University, Allston, MA 02134, USA., Gottlieb AP; John A Paulson School of Engineering & Applied Sciences, Harvard University, Allston, MA 02134, USA., Dowling DJ; Precision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA 02115, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA., Mitragotri S; John A Paulson School of Engineering & Applied Sciences, Harvard University, Allston, MA 02134, USA; Wyss Institute of Biologically Inspired Engineering, Boston, MA 02215, USA. Electronic address: mitragotri@seas.harvard.edu.
Jazyk: angličtina
Zdroj: Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2024 Dec; Vol. 376, pp. 632-645. Date of Electronic Publication: 2024 Oct 25.
DOI: 10.1016/j.jconrel.2024.10.038
Abstrakt: Vaccination is an important strategy for the prevention of infectious diseases worldwide. Adjuvants can be incorporated in vaccine formulations to enhance the resultant immune response and subsequently confer more robust protection upon natural infection. While adjuvants have exciting potential to improve vaccination, the landscape of materials employed in clinical adjuvants is small and its expansion is needed to facilitate vaccine development against current and future infectious diseases. This study introduces the first ionic liquid (IL) adjuvant comprised of choline and sorbic acid (ChoSorb) to produce an antigen-specific cellular as well as humoral immune response against multiple antigens. The abilities of ChoSorb as a vaccine adjuvant is evaluated and characterized through material analysis, innate immune responses, and adaptive responses to both a model and clinical grade antigen. With the robust immune responses generated by ChoSorb and the accompanying mechanistic insights, this study introduces ILs as a new class of adjuvant materials for future vaccine design.
Competing Interests: Declaration of competing interest SM and MG are inventors on a patent application describing the results in the manuscript (owned and managed by Harvard University). SM is a shareholder, advisor or board member of Liquideon LLC, Cage Bio, inTumo Therapeutics and i2o Therapeutics. DJD holds patents related to various adjuvantation and vaccine development strategies, filed and held by Children's Medical Center Corporation. DJD has served as a consultant for Merck Research Laboratories/Merck Sharp & Dohme Corp. (a Merck & Co., Inc. subsidiary), is a member of the scientific advisory board of EdJen BioTech, and is a co-founder of Ovax, Inc.
(Copyright © 2024 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: